Immunic (IMUX) announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, has been published in the ...

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its CEO as the company advances its multiple sclerosis treatment candidate through late-stage development and ...

Immunic, Inc. (NASDAQ:IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million. Immunic reported that the first ...

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line Phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Immunic ( (IMUX)) just unveiled an update. Immunic, Inc., a Nasdaq-listed late-stage ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

One stock that might be an intriguing choice for investors right now is Immunic, Inc. IMUX. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...

NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic ...

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, ...

Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition ...

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus ...